Technology

Optimized for actionability

Delve Decide’s bioinformatic pipeline, curated pathogen database and clinical interpretation software are robust, fast and reliable. Delve Decide rapidly analyzes DNA and RNA, sorting millions of sequences to identify the genetic signatures of potential pathogens using a broad, curated database, delivering comprehensive microbial analysis impossible through conventional hypothesis-guided testing.

World-class genomic sequencing

Delve Bio has partnered with Broad Clinical Labs, a CLIA-licensed and CAP-accredited, wholly owned subsidiary of the Broad Institute of MIT and Harvard for sample processing and sequencing. Broad Clinical Labs brings more than three decades of experience at the cutting edge of genomic research and application to all Delve’s customers.

Learn more

Generate optimized sequence data

Specialized sample processing includes enrichment for RNA and DNA pathogens. The process is optimized for sensitivity, specificity, and contamination-free sequence data.

Detect potential pathogen sequences

Preprocessing filtering and human host background subtraction quickly focuses on potential pathogens.

Identify likely pathogens

A custom-curated database covering more than 68,000 known and emerging pathogens, followed by additional filtering and taxonomic classification identifies pathogens present.

Automated identification

Automated bioinformatics matches sequences to the curated database, identifying bacteria, fungi, viruses and parasites.

Decide next steps

Results including quality control metrics, read counts, and alignment of reads, are reviewed and interpreted by our experts in infectious disease and microbiology ensures that results are clinically relevant and actionable.

Detect, identify and decide

Delve Decide is the proprietary platform that powers Delve Bio’s metagenomic testing, built to deliver unrivaled accuracy, reliability and speed.